An analysis of current pharmaceutical industry practices for making clinical trial results publicly accessible

Contemporary Clinical Trials

Volumn 30, Issue 4, 2009, Pages 293-299

  Viereck, Christopher ^a   Boudes, Pol ^b  

^a Founder and Principal   (United States)

^b NONE   (United States)

Author keywords

Clinical trial; Clinical trial reports; Clinical trial results; Clinical trial results databases; Clinical trial transparency; FDA Amendments Act, 2007; Pharmaceutical company practices; Public accessibility

Indexed keywords

ADALIMUMAB; DORIPENEM; GEFITINIB; INSULIN GLARGINE; LAPATINIB; RALTEGRAVIR; VARENICLINE; ZOLEDRONIC ACID;

ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DRUG INDUSTRY; DRUG INFORMATION; HUMAN; INFORMATION SYSTEM; INTERNET;

CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; DISCLOSURE; DRUG INDUSTRY; DRUG THERAPY; HUMANS; INTERNET; PHYSICIAN'S PRACTICE PATTERNS; PUBLIC POLICY;

EID: 67349216172     PISSN: 15517144     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2009.03.010     Document Type: Article

References (18)

1. Curfman G.D., Morrissey S., and Drazen J.M. Expression of concern reaffirmed. N Engl J Med 354 (2006) 1193
2. Anonymous. Is GSK guilty of fraud?. Lancet 363 (2004) 1919
3. Bouchie A. Clinical trial data: to disclose or not to disclose?. Nature Biotech 24 (2006) 1058-1060
4. Zarin D.A., and Tse T. Moving toward transparency of clinical trials. Science 319 (2008) 1340-1342
5. International Federation of Pharmaceutical Manufacturers and Associations. Joint position on the disclosure of clinical trial information via clinical trial registries and databases. Announced January 6 (2005). http://clinicaltrials.ifpma.org Available at: http://clinicaltrials.ifpma.org
6. Krleza-Jeric K., Chan A.-W., Dickersin K., et al. Principles for internal registration of protocol information and results from human trials of health related interventions: Ottawa statement (part 1). Br Med J 330 (2005) 956-958
7. Nathan D.M. Rosiglitazone and cardiotoxicity-weighting the evidence. New Engl J Med 357 (2007) 64-66
8. Turner E.H., Matthews A.M., Linardatos E., Tell R.A., and Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 358 (2008) 252-260
9. Food and Drug Administration Amendments Act-Public Law No. 110-85 § 801 (2007). http://www.fda.gov/oc/initiatives/HR3580.pdf Available at: http://www.fda.gov/oc/initiatives/HR3580.pdf
10. Chan A.W., Hrobjartsson A., Haahr M.T., Gotzsche P.C., and Altman D.G. Empirical evidence for selective reporting of outcomes in randomized trials. JAMA 291 (2004) 2451-2465
11. Office of the New York State Attorney General. Settlement sets new standard for release of drug information. Glaxo to establish "clinical trials register" with information on all company drugs. Announced August 26 (2004). http://www.oag.state.ny.us Available at http://www.oag.state.ny.us
12. International Federation of Pharmaceutical Manufacturers and Associations. New IFPMA clinical trials portal upgrade allows patients and physicians to search faster, more precisely and in five languages. Announced March 22 (2006). http://clinicaltrials.ifpma.org Available at http://clinicaltrials.ifpma.org.
13. National Library of Medicine, National Institutes of Health. ClinicalTrials.gov to include basic results data. Announced October 22, 2008. Accessed 11/19/08. Available at http://www.nlm.nih.gov
14. International Conference on Harmonisation. ICH Technical Requirements for Registration of Pharmaceuticals for human use. ICH harmonised tripartite guideline Structure and content of clinical study reports E3. Dated November 30 (1995). http://www.ich.org Available at http://www.ich.org
15. Health Canada Benchmark Survey to identify end user needs for the registration and disclosure of clinical trial information (September (2005). http://www.hc-sc.gc.ca/dhp-mps/prodpharma/activit/proj/enreg-clini-info/questionnaire_report-eng.php Available at: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/activit/proj/enreg-clini-info/questionnaire_report-eng.php (Accessed 3/17/09)
16. Maine Center for Disease Control and Prevention. An act regarding advertising by drug manufacturers and disclosure of clinical trials. Accessed 11/19/08. Available at http://www.state.me.us/dhhs.
17. Top Search Engine Share Trend, April, 2008-February, 2009. Available at: http://marketshare.hitslink.com/search-engine-market-share.aspx?qprid=5. Accessed March 17, 2009.
18. US Department of Justice. Pharmaceutical company cephalon to pay $425 million for off-label drug marketing. Announced September 29 (2008). http://www.usdoj.gov Available at: http://www.usdoj.gov